Quince Therapeutics (QNCX)
NASDAQ:QNCX
Want to see QNCX full AI Analyst Report?
Total Valuation
Quince Therapeutics has a market cap or net worth of $21.03M. The enterprise value is $19.40M.
Market Cap$21.03M
Enterprise Value$19.40M
Share Statistics
Quince Therapeutics has 16,300,795 shares outstanding. The number of shares has decreased by -2.65% in one year.
Shares Outstanding16,300,795
Owned by Insiders50.75%
Owned by Institutions―
Financial Efficiency
Quince Therapeutics’s return on equity (ROE) is 2.35 and return on invested capital (ROIC) is -73.81%.
Return on Equity (ROE)2.35
Return on Assets (ROA)-0.90
Return on Invested Capital (ROIC)-73.81%
Return on Capital Employed (ROCE)-1.00
Revenue Per Employee0.00
Profits Per Employee-2.33M
Employee Count36
Asset Turnover0.00
Inventory Turnover0.00
Valuation Ratios
The current PE Ratio of Quince Therapeutics is ―. Quince Therapeutics’s PEG ratio is -0.07.
PE Ratio―
PS Ratio0.00
PB Ratio-4.70
Price to Fair Value-4.70
Price to FCF-4.02
Price to Operating Cash Flow-0.14
PEG Ratio-0.07
Income Statement
In the last 12 months, Quince Therapeutics had revenue of 0.00 and earned -83.98M in profits. Earnings per share was -16.80.
Revenue0.00
Gross Profit-142.00K
Operating Income-50.43M
Pretax Income-80.77M
Net Income-83.98M
EBITDA-50.29M
Earnings Per Share (EPS)-16.80
Cash Flow
In the last 12 months, operating cash flow was -47.91M and capital expenditures -209.00K, giving a free cash flow of -48.12M billion.
Operating Cash Flow-47.91M
Free Cash Flow-48.12M
Free Cash Flow per Share-2.95
Dividends & Yields
Quince Therapeutics pays an annual dividend of ―, resulting in a dividend yield of ―
Dividend Per Share―
Dividend Yield―
Payout RatioN/A
Free Cash Flow Yield―
Earnings Yield―
Stock Price Statistics
Beta0.34
52-Week Price Change-88.82%
50-Day Moving Average1.41
200-Day Moving Average16.44
Relative Strength Index (RSI)43.25
Average Volume (3m)8.95M
Important Dates
Quince Therapeutics upcoming earnings date is May 19, 2026, After Close (Confirmed).
Last Earnings DateMar 3, 2026
Next Earnings DateMay 19, 2026
Ex-Dividend Date―
Financial Position
Quince Therapeutics as a current ratio of 0.53, with Debt / Equity ratio of -51.40%
Current Ratio0.53
Quick Ratio0.53
Debt to Market Cap0.11
Net Debt to EBITDA-0.25
Interest Coverage Ratio0.00
Taxes
In the past 12 months, Quince Therapeutics has paid 3.21M in taxes.
Income Tax3.21M
Effective Tax Rate-0.04
Enterprise Valuation
Quince Therapeutics EV to EBITDA ratio is -3.59, with an EV/FCF ratio of -4.32.
EV to Sales0.00
EV to EBITDA-3.59
EV to Free Cash Flow-4.32
EV to Operating Cash Flow-4.35
Balance Sheet
Quince Therapeutics has $17.75M in cash and marketable securities with $18.36M in debt, giving a net cash position of -$604.00K billion.
Cash & Marketable Securities$17.75M
Total Debt$18.36M
Net Cash-$604.00K
Net Cash Per Share-$0.04
Tangible Book Value Per Share-$20.67
Margins
Gross margin is 0.00%, with operating margin of 0.00%, and net profit margin of 0.00%.
Gross Margin0.00%
Operating Margin0.00%
Pretax Margin0.00%
Net Profit Margin0.00%
EBITDA Margin0.00%
EBIT Margin0.00%
Analyst Forecast
The average price target for Quince Therapeutics is ―, which is 11.43% higher than the current price. The consensus rating is Moderate Sell
Price Target―
Price Target Upside―
Analyst ConsensusModerate Sell
Analyst Count3
Revenue Growth Forecast―
EPS Growth Forecast-25.06%